Video

Urology Times 50 Innovations Series: Cryotherapy for kidney and prostate cancer

Author(s):

Urology Times staff

"Cryotherapy was the first energy source that we were able to ablate tissues with in either the kidney or prostate and understand what that ablation would do," says J. Stephen Jones, MD, FACS.

Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, J. Stephen Jones, MD, FACS, discusses the development of cryotherapy for the treatment of kidney and prostate cancers. Jones is president and CEO of Inova Health System.

Related Videos
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Dr Louise Kostos answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
Related Content
Urologists perform first remote robot-assisted HIFU for prostate cancer
April 17th 2025

Urologists perform first remote robot-assisted HIFU for prostate cancer

Hannah Clarke
“We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Study underway to assess 3-fraction SBRT regimen in prostate cancer
April 14th 2025

Study underway to assess 3-fraction SBRT regimen in prostate cancer

Hannah Clarke
"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Genetic test can predict risk of toxicity following radiation for prostate cancer
April 7th 2025

Genetic test can predict risk of toxicity following radiation for prostate cancer

Hannah Clarke
"This finding reinforces PROSTOX ultra as a true measure of the biological response to radiation, independent of treatment era or technique that can identify the safest course of treatment to avoid toxicity," says Amar U. Kishan, MD.
What urologists can expect in Q2 of 2025
April 7th 2025

What urologists can expect in Q2 of 2025

Hannah Clarke Benjamin P. Saylor
A lookahead of the notable FDA decisions and conferences slated for Q2 2025.
© 2025 MJH Life Sciences

All rights reserved.